KRAS mutant lung cancer: progress thus far on an elusive therapeutic target
AbstractThe KRAS mutation remains the most common driver mutation in patients with non‐small cell lung cancer (NSCLC) and confers a poor prognosis. Thus far, efforts to target this mutation over the last two decades have been unsuccessful. Over the past 5 years, many efforts to develop drugs that ta...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2015-12-01
|
| Series: | Clinical and Translational Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s40169-015-0075-0 |
| _version_ | 1818488224212844544 |
|---|---|
| author | Saveri Bhattacharya Mark A. Socinski Timothy F. Burns |
| author_facet | Saveri Bhattacharya Mark A. Socinski Timothy F. Burns |
| author_sort | Saveri Bhattacharya |
| collection | DOAJ |
| description | AbstractThe KRAS mutation remains the most common driver mutation in patients with non‐small cell lung cancer (NSCLC) and confers a poor prognosis. Thus far, efforts to target this mutation over the last two decades have been unsuccessful. Over the past 5 years, many efforts to develop drugs that target the RAS‐RAF‐MEK‐ERK (MAPK) pathway have resulted in enhanced understanding of the KRAS mutant NSCLC and have provided optimism that this disease can be targeted. |
| first_indexed | 2024-12-10T16:48:15Z |
| format | Article |
| id | doaj.art-4f4f06d5ae524bfda040dee3b922cc17 |
| institution | Directory Open Access Journal |
| issn | 2001-1326 |
| language | English |
| last_indexed | 2024-12-10T16:48:15Z |
| publishDate | 2015-12-01 |
| publisher | Wiley |
| record_format | Article |
| series | Clinical and Translational Medicine |
| spelling | doaj.art-4f4f06d5ae524bfda040dee3b922cc172022-12-22T01:41:00ZengWileyClinical and Translational Medicine2001-13262015-12-0141n/an/a10.1186/s40169-015-0075-0KRAS mutant lung cancer: progress thus far on an elusive therapeutic targetSaveri Bhattacharya0Mark A. Socinski1Timothy F. Burns2University of Pittsburgh Cancer Institute5150 Centre Avenue, Room 46115232PittsburghPAUSAMedicine and Cardiothoracic SurgeryUniversity of Pittsburgh Cancer Institute5150 Centre Avenue, Room 55615232PittsburghPAUSAUniversity of Pittsburgh Cancer Institute5117 Centre Avenue, Office: Suite 2.18e15232PittsburghPAUSAAbstractThe KRAS mutation remains the most common driver mutation in patients with non‐small cell lung cancer (NSCLC) and confers a poor prognosis. Thus far, efforts to target this mutation over the last two decades have been unsuccessful. Over the past 5 years, many efforts to develop drugs that target the RAS‐RAF‐MEK‐ERK (MAPK) pathway have resulted in enhanced understanding of the KRAS mutant NSCLC and have provided optimism that this disease can be targeted.https://doi.org/10.1186/s40169-015-0075-0KRAS mutant NSCLCMAPK pathwayTargeted therapy |
| spellingShingle | Saveri Bhattacharya Mark A. Socinski Timothy F. Burns KRAS mutant lung cancer: progress thus far on an elusive therapeutic target Clinical and Translational Medicine KRAS mutant NSCLC MAPK pathway Targeted therapy |
| title | KRAS mutant lung cancer: progress thus far on an elusive therapeutic target |
| title_full | KRAS mutant lung cancer: progress thus far on an elusive therapeutic target |
| title_fullStr | KRAS mutant lung cancer: progress thus far on an elusive therapeutic target |
| title_full_unstemmed | KRAS mutant lung cancer: progress thus far on an elusive therapeutic target |
| title_short | KRAS mutant lung cancer: progress thus far on an elusive therapeutic target |
| title_sort | kras mutant lung cancer progress thus far on an elusive therapeutic target |
| topic | KRAS mutant NSCLC MAPK pathway Targeted therapy |
| url | https://doi.org/10.1186/s40169-015-0075-0 |
| work_keys_str_mv | AT saveribhattacharya krasmutantlungcancerprogressthusfaronanelusivetherapeutictarget AT markasocinski krasmutantlungcancerprogressthusfaronanelusivetherapeutictarget AT timothyfburns krasmutantlungcancerprogressthusfaronanelusivetherapeutictarget |